Pharmacotherapeutic options in the treatment of nocturia: an update on the current oral drug therapies

References

• Hashim H, Blanker MH, Drake MJ, et al. International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function. Neurourol Urodyn. 2019;38(2):499–508.
   PubMed Web of Science ®Google Scholar
• Drangsholt S, Ruiz MJA, Peyronnet B, et al. Diagnosis and management of nocturia in current clinical practice: who are nocturia patients, and how do we treat them? World J Urol. 2019 July;37(7):1389–1394.
   PubMed Web of Science ®Google Scholar
• Robinson D, Suman S. Managing nocturia: the multidisciplinary approach. Maturitas. 2018;116:123–129.
   PubMed Web of Science ®Google Scholar
• Everaert K, Hervé F, Bower W, et al. How can we develop a more clinically useful and robust algorithm for diagnosing and treating nocturia? ICI-RS 2017. Neurourol Urodyn. 2018;37(S4):S46–S59.
   PubMedGoogle Scholar
• Kowalik CG, Cohn JA, Delpe S, et al. Nocturia: evaluation and current management strategies. Rev Urol. 2018;20(1):1–6.
   PubMedGoogle Scholar
• Zhou J, Xia S, Li T, et al. Association between obstructive sleep apnea syndrome and nocturia: a meta-analysis. Sleep Breath. 2020;24(4):1293–1298.
   PubMed Web of Science ®Google Scholar
• Fitzgerald MP, Lemack G, Wheeler T, et al. Urinary incontinence treatment network. Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy. Int Urogynecol J Pelvic Floor Dysfunct. 2008 November;19(11):1545–1550.
   PubMed Web of Science ®Google Scholar
• Khizer Z, Sadia A, Sharma R, et al. Drug delivery approaches for managing overactive bladder (OAB): a systematic review. Pharmaceuticals (Basel). 2021;14(5):409.
   PubMedGoogle Scholar
• Gordon DJ, Emeruwa CJ, Weiss JP. Management strategies for nocturia. Curr Urol Rep. 2019;20(11):75.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Van Kerrebroeck P. Pharmacotherapy for nocturia. Curr Urol Rep. 2018;19(1):8.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence. 6th international consultation on incontinence, September2016. Tokyo: The International Continence Society (ICS)and the International Consultation on Urological Diseases (ICUD); 2017. p. 805–957.
   Google Scholar
• Ebell MH, Radke T, Gardner J. A systematic review of the efficacy and safety of desmopressin for nocturia in adults. J Urol. 2014;192(3):829–835.
   PubMed Web of Science ®Google Scholar
• Weiss JP, Juul KV, Wein AJ. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19–S24.
   PubMedGoogle Scholar
• Chung E. Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia. Exper Opin Pharmacol. 2018;19(3):291–298.
   PubMed Web of Science ®Google Scholar
• Zong H, Yang C, Peng X, et al. Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials. Int Urol Nephrol. 2012;44(2):377–384.
   PubMed Web of Science ®Google Scholar
• Cai X, Tian Y, Nie M, et al. Efficacy and safety of desmopressin in women with nocturia: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol. 2019;51(11):1913–1923.
   PubMed Web of Science ®Google Scholar
• Cornu JN, Abrams P, Chapple CR, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management- a systematic review and meta-analysis. Eur Urol. 2012;62(5):877–890.
   PubMed Web of Science ®Google Scholar
• Han J, Jung JH, Bakker CJ, et al. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev. 2017;10:CD012059.
   PubMedGoogle Scholar
• Kim JC, Cho KJ, Lee JG, et al. Efficacy and safety of desmopressin add-on therapy for men with persistent nocturia on α-blocker monotherapy for lower urinary tract symptoms: a randomized, double-blind placebo controlled study. J Urol. 2017;197(2):459–464.
   PubMed Web of Science ®Google Scholar
• Rovner ES, Raymond K, Andruczyk E, et al. Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study. Low Urin Tract Symptoms. 2018;10(3):221–230.
   PubMed Web of Science ®Google Scholar
• Yamaguichi O, Nishizawa O, Juul KV, et al. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int. 2013;111(3):474–484.
   PubMed Web of Science ®Google Scholar
• Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2014;172:1021–1025.
   Web of Science ®Google Scholar
• Juul KV, Klein BM, Noorgaard JP. Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn. 2013;32:363–370.
   PubMed Web of Science ®Google Scholar
• Juul KV, Klein BM, Sandström R, et al. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol. 2011;300(5):F1116–F1122.
   PubMed Web of Science ®Google Scholar
• Juul KV, Malmberg A, van der Meulen E, et al. Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia. BJU Int. 2017;119(5):776–784.
   PubMed Web of Science ®Google Scholar
• McElwaine-Johnn H, Schutz R, Yea C, et al. The antidiuretic effect of fedovapagon can be effectively controlled by dose. Abstr ICS Florence. 2017.
   Google Scholar
• Golor G, McElwaine-Johnn H, Handy R, et al. Administration of fedovapagon causes a dose-responsive reduction in nocturnal polyuria index. J Urol. 2013;189(4 Suppl.1):e930–931.
   Web of Science ®Google Scholar
• Cheng CJ, Rodan AR, Huang CL. Emerging targets of diuretic therapy. Clin Pharmacol Ther. 2017;102(3):420–435.
   PubMed Web of Science ®Google Scholar
• Reynard JM, Cannon A, Yang Q, et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol. 1998;81(2):215–218.
   PubMedGoogle Scholar
• Fu FG, Lavery HJ, Wu DL. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:437–452.
   Web of Science ®Google Scholar
• Pedersen PA, Johansen B. Prophylactic treatment of adult nocturia with bumetanide. Br J Urol. 1988;62(2):145–147.
   PubMedGoogle Scholar
• Rackley R, Weiss JP, Rovner ES, et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67(4):731–736.
   PubMed Web of Science ®Google Scholar
• Weiss JP, Jumadilova Z, Johnson TM 2nd, et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. J Urol. 2013;189(4):1396–1401.
   PubMed Web of Science ®Google Scholar
• Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67(2):275–280.
   PubMed Web of Science ®Google Scholar
• Khusid JA, Weiss JP, Carlsson MO, et al. Fesoterodine for the treatment of nocturnal urgency in patients with overactiveb ladder syndrome: an analysis of responders and nonresponders. J Urol. 2017;198(5):1119–1123.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010;75(1):62–68.
   PubMed Web of Science ®Google Scholar
• Yokoyama O, Yamaguchi O, Kakizaki H, et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol. 2011;186(1):170–174.
   PubMed Web of Science ®Google Scholar
• Kwon T, Oh TH, Choi S, et al. Influence of daytime or nightime dosing with solifenacin for overactive bladder with nocturia: impact on nocturia and sleep quality. J Korean Med Sci. 2017;32(9):1491–1495.
   PubMed Web of Science ®Google Scholar
• Brubaker L, FitzGerald M. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(7):737–741.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–1458.
   PubMed Web of Science ®Google Scholar
• Petrossian RA, Dynda D, Delfino K, et al. Mirabegron improves sleep measures, nocturia, and lower urinary tract symptoms in those with urinary symptoms associated with disordered sleep. Can J Urol. 2020;27(1):10106–10117.
   PubMed Web of Science ®Google Scholar
• Lee CL, Ong HL, Kuo HC. Therapeutic efficacy of mirabegron 25mg monotherapy in patients with nocturia-predominant hypersensitive bladder. Ci Ji Yi Xue Za Zhi. 2019;32(1):30–35.
   Google Scholar
• Suzuki T, Minagawa T, Saito T, et al. Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: a multicenter randomized trial. Int J Urol. 2021;28(9):944–949.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Cruz F, Fusco F. α1-Blockers in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: is silodosin different? Adv Ther. 2017;33(12):2110–2121.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007;4(7):368–378.
   PubMedGoogle Scholar
• Kim BH, Kim KH, Ko YH, et al. The prostatic urethral angle can predict the response to alpha adrenoceptor antagonist monotherapy for treating nocturia in men with lower urinary tract symptom: a multicenter study. Prostate Int. 2016;4(1):30–35.
   PubMed Web of Science ®Google Scholar
• Kim YW, Park J, Chung H, et al. The effectiveness of silodosin for nocturnal polyuria in elderly men with benign prostatic hyperplasia: a multicenter study. Int Neurourol J. 2015;19(3):190–196.
   PubMed Web of Science ®Google Scholar
• Eisenhardt A, Schneider T, Cruz F, et al. Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol. 2014;32(5):1119–1125.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Montorsi F, Tammela TL, et al. European Silodosin Study Group Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–352.
   PubMed Web of Science ®Google Scholar
• Kim SO, Choi HS, Kwon D. The α1 adrenoceptor antagonist tamsulosin for the treatment of voiding symptoms improves nocturia and sleep quality in women. Urol J. 2014;11(3):1636–1641.
   PubMed Web of Science ®Google Scholar
• Füllhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013;64(2):228–243.
   PubMed Web of Science ®Google Scholar
• Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers. Eur Urol. 2009;56(3):534–543.
   PubMed Web of Science ®Google Scholar
• Johnson TM 2nd, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the department of veterans affairs cooperative study trial. J Urol. 2003;170(1):145–148.
   PubMed Web of Science ®Google Scholar
• Johnson ITM, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride, and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007;178(5):2045–2051.
   PubMed Web of Science ®Google Scholar
• Oelke M, Roehrborn CG, D’Ancona C, et al. Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies. World J Urol. 2014;32(5):1141–1147.
   PubMed Web of Science ®Google Scholar
• Kuhlman PK, Fischer SC, Howard LE, et al. Dutasteride improves nocturia but does not lead to better sleep: results from the REDUCE clinical trial. J Urol. 2021;205(6):1733–1739.
   PubMedGoogle Scholar
• Giuliano F, Uckert S, Maggi M, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63(3):506–516.
   PubMed Web of Science ®Google Scholar
• Oelke M, Weiss JP, Mamoulakis C, et al. Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. World J Urol. 2014;32(5):1127–1132.
   PubMed Web of Science ®Google Scholar
• Takahashi R, Sumino Y, Miyazato M, et al. Tadalafil improves nocturia and nocturia-related quality of life in patients with benign prostatic hyperplasia (KYU-PRO study). Urol Int. 2020;104(7–8):587–593.
   PubMed Web of Science ®Google Scholar
• Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927–947.
   PubMed Web of Science ®Google Scholar
• Asplund R, Johansson S, Henriksson S, et al. Nocturia, depression and antidepressant medications. BJU Int. 2005;95(6):820–823.
   PubMed Web of Science ®Google Scholar
• Witkin JM, Smith JL, Golani LK, et al. Involvement of muscarinic receptor mechanisms in antidepressant drug action. Adv Pharmacol. 2020;89:311–356.
   PubMedGoogle Scholar
• You SH, Jeong HJ. The clinical effects of amitriptyline on the nocturia of patients with benign prostatic hyperplasia. Korean J Urol. 2008;49(4):343–349.
   Google Scholar
• Pevet P, Challet E, Felder-Schmittbuhl MP. Melatonin and the circadian system: keys for health with a focus on sleep. Handb Clin Neurol. 2021;179:331–343.
   PubMedGoogle Scholar
• Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol. 2004;171(3):1199–1202.
   PubMed Web of Science ®Google Scholar
• Drake MJ, Canham L, Cotterill N, et al. Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of nocturia in adults with multiple sclerosis (MeNiMS. BMC Neurol. 2018;18(1):107.
   PubMedGoogle Scholar
• Batla A, Simeoni S, Uchiyama T, et al. Exploratory pilot of exogenous sustained-release melatonin on nocturia in Parkinson’s disease. Eur J Neurol. 2021;28(6):1884–1892.
   PubMed Web of Science ®Google Scholar
• Sugaya K, Nishijima S, Miyazato M, et al. Effects of melatonin and rilmazafone on nocturia in the elderly. J Int Med Res. 2007;35(5):685–691.
   PubMed Web of Science ®Google Scholar